KalVista Pharmaceuticals Inc. (KALV) is having a pretty good launch moment. The biotech company reported Thursday that its hereditary angioedema treatment EKTERLY pulled in about $35 million in fourth-quarter revenue and $49 million for the full fiscal year 2025, just months after hitting the market in July.
For context, EKTERLY is the first and only oral on-demand treatment for hereditary angioedema, a rare condition that causes recurrent episodes of severe swelling. The FDA approved it in July 2025 for acute attacks in adults and kids aged 12 and up, which was a big deal because patients previously had limited options for quick relief during attacks.
The early adoption numbers look solid. Through year-end, KalVista recorded 1,318 patient start forms and activated 580 unique prescribers across the U.S. market. More interesting: by the fourth quarter, prescription refills had overtaken new prescriptions as the main revenue driver. That's usually a good sign that patients are sticking with the treatment rather than trying it once and moving on. The company did note that some of this activity might have been pulled forward ahead of the holidays, so there could be some timing quirks in the data.
KalVista isn't just focused on the U.S. market. The company granted Multicare Pharmaceuticals exclusive rights to commercialize sebetralstat (EKTERLY's generic name) throughout Latin America. Under that deal, Multicare will handle regulatory approvals and distribution in Brazil, Argentina, Colombia, and Mexico.
There's also a pediatric expansion in the works. The company finished enrollment in its Phase 3 KONFIDENT-KID trial evaluating sebetralstat in children aged two to 11, wrapping up a full year ahead of schedule. KalVista expects to submit a new drug application for the pediatric indication in the third quarter of 2026, with a potential U.S. launch targeted for 2027.
Price Action: KalVista Pharmaceuticals stock jumped 13.18% to $17.86 on Friday following the announcement.
